NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)

Active Not RecruitingPhase 1

Sponsor: Merck Sharp & Dohme LLC

Conditions: Diabetes Mellitus, Type 2

Interventions: MK-1403 + additive coformulation, Placebo + additive coformulation

Countries: United States

The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-1403. The study will also measure what happens to MK-1403 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Has a confirmed diagnosis of Type 2 diabetes mellitus (T2DM)
* Has body mass index (BMI) between 18 and 40 kg/m\^2, inclusive

Exclusion Criteria:

* Has Type 1 diabetes mellitus or secondary types of diabetes
* Has a history of congestive heart failure (New York Heart Association \[NYHA\] Class 3 or 4)
* Has history of myocardial infarction, uncontrolled arrhythmias, cardiac revascularization, angina, unstable peripheral arterial disease and/or stroke
* Has history of cancer (malignancy)
* Has positive test(s) for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or human immunodeficiency virus (HIV)
* Has a history of gastrointestinal (GI) disease which might affect food and drug absorption, or has had gastric bypass or similar surgery

Locations (5)

Anaheim, California, United States
Chula Vista, California, United States
Miami, Florida, United States
South Miami, Florida, United States
Springfield, Missouri, United States